The abdomen is easy to see and easy to rotate The abdomen is a common GLP1 injection area because it is visible, reachable, and has plenty of room for rotation
5,6 However, persistence appears to be improving
Research has demonstrated that retatrutide can lead to significant weight loss, with clinical trials showing participants achieving an average weight reduction of X% over a period of Y months
Side Effect Mitigation The primary motivation for microdosing is reducing adverse effects: Theoretical advantages: Lower peak concentrations reduce nausea intensity Gradual exposure allows GI adaptation Reduced gastroparesis severity Better maintenance of normal eating patterns 2
The increase was larger at higher doses, peaked after 24 weeks of treatment, then went down later in the trial
But, as she says, 'it didn't change the fact that nothing worked.' Following this Knudsen got roped into the team's effort to improve a native GLP-1 peptide licensed from MGH